Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ROS1 inhibitor JYP0322

An orally available selective inhibitor of the receptor tyrosine kinase c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, ROS1 inhibitor JYP0322 targets, binds to and inhibits ROS1. This inhibits proliferation of ROS1-driven tumor cells. ROS1, overexpressed, rearranged and/or mutated in certain cancer cells, plays a key role in cell growth and survival of various types of cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	JYP 0322 JYP-0322 JYP0322

ROS1 inhibitor JYP0322

Search NCI's Drug Dictionary